VanEck Genomics and Healthcare Innovators UCITS ETF

PhysicalIndex replication
AccumulatingDistribution policy
0.35 %TER
£17.83M Fund size
49Number of positions
— TD
61.45 %Top 10 share
USDCurrency
5SRI

Current price

£19.24
19 Nov 2026
1D
1W
1M
3M
6M
1Y
3Y
Max

Description

The Fund’s investment objective is to replicate, before fees and expenses, the MVIS Global Future Healthcare ESG Index (the “Index”). In order to seek to achieve its investment objective, the Manager will normally use a replication strategy by investing directly in the underlying equity securities of the MVIS Global Future Healthcare ESG Index (the “Index”) being the stock, American depository receipts (ADRs), and global depository receipts (GDRs). Such equity securities must be issued by companies who generate at least 50% (25% for current components) of their revenues from the following sub-themes: (A) Healthcare therapies based on the targeting or modification of genetic makeup of cells or uses mRNA (B) Technology platforms that enable the development of genetics-based healthcare therapies (C) Laboratory equipment or services used to test, code, or develop genetics-based healthcare therapies (D) Software used to facilitate online medical consultations (E) E-Commerce pharmacies (F) Software for the management of medical practices and/or patient records (G) Outpatient medical Internet of Things devices which allow remote monitoring of health indicators such as heart rate and rhythm, or glucose levels, and be listed or traded on the Markets referred to in Appendix II of the Prospectus. The Manager has categorised the Fund as meeting the provisions set out in Article 9(1) of Regulation (EU) 2019/2088 on sustainability related disclosures in the financial services sector ("SFDR") for products, which have sustainable investment as their objective and where an index has been designated as a reference benchmark. The Index Provider utilizes ESG data provided by ISS, a ratings company which identifies ESG compliant companies for the Index Provider. The Index Provider utilizes ESG data provided by Institutional Shareholder Services group of companies (ISS). ISS provides the Index Provider with high-quality data, analytics and insight, including country ESG research and ratings enabling the Index Provider to identify material social and environmental risks and opportunities. The Index does not consider companies that violate certain ESG criteria. Companies with very severe social norms violations, have greater than 0% revenue exposure to controversial weapons, or that exceed certain thresholds of revenue exposure to various sectors including but not limited to civilian firearms, military equipment, tobacco, and energy extractives are not eligible for inclusion. Further, companies that are not covered by ISS or for which all relevant data fields are not collected by ISS may be eligible for inclusion. In these cases the Index Provider will review the impact and will act on best efforts basis to ensure data coverage or seek proxy data. Where it is not practical or cost efficient for the Fund to fully replicate the Index, the Manager may utilise an optimised sampling methodology. The Fund may also (or alternatively) invest in financial derivative instruments (FDIs) which relate to the Index or constituents of the Index. The FDIs which the Fund may use are futures, options (puts and calls), swaps (including equity swaps and swaps on the Index), currency forwards and non-deliverable forwards (a forward contract that does not require settlement on maturity) (NDFs). The Fund may also invest in ancillary liquid assets and money market instruments which may include bank deposits, depositary receipts, certificates of deposit, fixed or floating rate instruments (treasury bills), commercial paper, floating rate notes and freely transferable promissory notes. The ancillary liquid assets, money market instruments and FDI (other than permitted unlisted investments) will be listed or traded on the Markets referred to in Appendix II of the Prospectus. The Fund may invest up to 20% of its Net Asset Value in securities issued by the same body. This limit may be raised to 35% for a single issuer when exceptional market conditions apply which may include the dominance of a particular issuer in the relevant market. Furthermore, the Fund may not invest less than 51% of its Net Asset Value in equity securities which constitute "equity participation" within the meaning of section 2, Article 8 of the German Investment Tax Act. The Fund, using a “passive” or indexing investment approach, attempts to approximate the investment performance of the Index by investing in a portfolio of securities that generally replicates the Index. The Investment Manager will regularly monitor the Fund’s tracking accuracy. Recommendation: This Fund may not be appropriate for investors who plan to withdraw their money within 5 years. Fund’s base currency: U.S. Dollar Distribution policy: Income accumulated

Return

Here you can see the performance (incl. distributions) of the VanEck Genomics and Healthcare Innovators UCITS ETF.

Period Perfor­mance
1 Week-6.10 %
1 Month-8.96 %
3 Months-5.08 %
6 Months+33.70 %
1 Year+13.76 %
3 Years+37.77 %(11.27 % p.a.)
5 Years—
10 Years—
Since inception +10.80 %(2.46 % p.a.)
Year Perfor­mance
YTD+16.34 %
2025+3.75 %
2024+1.21 %
2023-8.02 %
2022-0.08 %
2021—
As of: 19 Nov 2026. Performance displayed in GBP

Master data

Key master data for the VanEck Genomics and Healthcare Innovators UCITS ETF

Total expense ratio (TER) 0.35 %
Index replication Physical
Replication method Full
Distribution policy Accumulating
Fund size £17.83M
Fund launch 2 Sept 2022
Fund currency USD
Currency hedging No 
Fund domicileIrland
Risk indicator (SRI)
5 · medium-high risk class

Risk metrics

Key risk and analysis metrics for the VanEck Genomics and Healthcare Innovators UCITS ETF

Volatility
25.17 % 1 Year
20.52 % 3 Years
— 5 Years
max. Drawdown
-14.99 % 1 Year
-14.99 % 3 Years
— 5 Years
Sharpe Ratio
1.02 1 Year
0.82 3 Years
— 5 Years
XLM
67.40

Information about the MVIS Global Future Healthcare ESG EUR Index

Index name MVIS Global Future Healthcare ESG EUR (1)
Included securities 55
Stock positions 49
Bond positions 0
Cash and other positions 6

More ETFs tracking the MVIS Global Future Healthcare ESG EUR Index

Here you can find alternative index funds for the MVIS Global Future Healthcare ESG EUR.

Fund nameWKNTER
No results

Frequently asked questions

Here you will find all answers to your questions about the VanEck Genomics and Healthcare Innovators UCITS ETF

Master data is provided by Morningstar (stocks, ETFs, funds), CoinGecko (cryptocurrencies) and Isarvest GmbH. Price data is at least 15-minute delayed exchange prices (stocks, ETFs, funds) or NAV prices (ETFs, funds). Real-time prices – where available – are provided by the providers and Lang & Schwarz (stocks, ETFs, funds) and CoinGecko (cryptocurrencies).

Isarvest GmbH assumes no liability for the information presented and cannot guarantee that the data is complete and accurate.

Affiliate notice *
Links marked with an asterisk (*) are advertising or affiliate links. If you purchase or sign up through this link, we receive compensation from the provider. This comes at no additional cost or disadvantage to you. We use this revenue to fund our free services. Thank you for your support.